The primary objective of this study is to assess the safety and key electrical performance of the INVICTA leads equipped with DF4 connector: ACTIVE fixation type models (single and dual coil: INVICTA 1CR, INVICTA 2CR)
APOLLO study is a pre-market approval (INVICTA leads - devices under investigation - are not CE marked), interventional, prospective, longitudinal, international (European), multicenter, single arm study. The devices under investigation, the INVICTA defibrillation leads, are new quadripolar leads, to be used with Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators (ICD/CRT-D). This clinical study intends to demonstrate safety and electrical performances of the INVICTA leads among the different models: active fixation either single coil (model 1CR) or dual coil (model 2CR)leads models. The clinical data will be used to support the application to CE marking of INVICTA leads. The primary endpoints will be evaluated at 3 months post-implantation; secondary endpoints will be evaluated up to 2 years post-implantation. A total number of 445 patients will be enrolled in the study, in up to 60 centers in Europe. The follow-up visits are scheduled at hospital discharge, at 1 month, at 3 months, at 6 months, at 12 months, at 18 months and at 24 months, post-implant
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
446
The implant or the attempt to implant an INVICTA lead
1.Freedom from INVICTA lead-related complications 1.Freedom from INVICTA lead-related complications [Time Frame: 90 days
Freedom from INVICTA lead-related complications as assessed by an independent events adjudicator and defined as any INVICTA lead-related serious adverse device effect (SADE) that resulted in patient death or required an additional invasive intervention
Time frame: 90 days
2.INVICTA lead electrical performance at 3 months
Right Ventricular (RV) pacing threshold (V) of the INVICTA lead, measured by the implanted ICD/CRT-D with 0.5 ms pulse width
Time frame: 3 months
INVICTA lead pacing threshold
RV lead pacing threshold amplitude (V), measured by the implanted ICD/CRT-D with 0.5 ms pulse width
Time frame: 24 months
INVICTA lead impedances
RV lead pacing impedance (Ohm) and defibrillation coil impedance (Ohm), measured by the implanted ICD/CRT-D
Time frame: 24 months
INVICTA sensing threshold
RV lead endocardial R wave amplitude (mV), measured by the implanted ICD/CRT-D
Time frame: 24 months
Percentage of the shocks that successfully terminate a ventricular arrhythmia episode
Percentage of endocardial shock therapies that successfully terminate ventricular arrhythmia episodes, calculated as the proportion of successful shocks on the total number of shocks delivered during defibrillation testing or spontaneous ventricular arrhythmias
Time frame: 24 months
Acute INVICTA lead complications
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Kepler Universitätsklinikum GmbH
Linz, Austria
CH Annecy
Annecy, France
CHU Brest
Brest, France
CHU Clermont- Ferrand
Clermont-Ferrand, France
CHU Grenoble
Grenoble, France
CHU Lille
Lille, France
Hôpital St Joseph
Marseille, France
CHU Strasbourg
Strasbourg, France
CHU Tours
Tours, France
RWTH Aachen
Aachen, Germany
...and 35 more locations
Assessment of Acute INVICTA lead complications
Time frame: 30 days
Chronic INVICTA lead complications
Assessment of Chronic INVICTA lead complications
Time frame: > 30 days
Daily INVICTA autothreshold values (V)
Assessment of Daily INVICTA autothreshold values (V)
Time frame: 1 month
.INVICTA lead handling assessment
Summary of the investigators' opinion about INVICTA handling at implant
Time frame: At implant (day 0)
INVICTA lead implant success rate
% of enrolled patients successfully implanted with an INVICTA lead
Time frame: At implant (day 0)
Serious Adverse Events up to 24 months
Report of SAEs occurred up to 24 months post-implantation
Time frame: 24 months